Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.82 |
| ▸ | NPC1 | O15118 | 8/20 | 0.82 |
| ▸ | RAB9A | P51151 | 8/20 | 0.82 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.82 |
| ▸ | LMNA | P02545 | 4/20 | 0.82 |
| ▸ | TP53 | P04637 | 4/20 | 0.82 |
| ▸ | HTT | P42858 | 4/20 | 0.82 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.82 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.82 |
| ▸ | CCR1 | P32246 | 3/20 | 0.82 |
| ▸ | CCR5 | P51681 | 3/20 | 0.82 |
| ▸ | CCR8 | P51685 | 3/20 | 0.82 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.82 |
| ▸ | ALPL | P05186 | 1/20 | 0.82 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.82 |
| ▸ | ALPI | P09923 | 1/20 | 0.82 |
| ▸ | ALPG | P10696 | 1/20 | 0.82 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.82 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.82 |
| ▸ | PKM | P14618 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3753259 | 1.00 | KDM4E (0.82) | KDM4ENPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL30211369 | 0.91 | KDM4E (1.00) | KDM4ENPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL30172832 | 0.91 | KDM4E (1.00) | KDM4ENPC1RAB9ASMN1; SMN2LMNA | |
| Terpyridine SCHEMBL29357603 | 0.91 | KDM4E (1.00) | KDM4ENPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL7964803 | 0.91 | KDM4E (1.00) | KDM4ENPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL1456985 | 0.91 | KDM4E (1.00) | KDM4ENPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL1456153 | 0.91 | KDM4E (1.00) | KDM4ENPC1RAB9ASMN1; SMN2LMNA | |
| Terpyridine SCHEMBL57442 | 0.91 | KDM4E (1.00) | KDM4ENPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL4174742 | 0.88 | KDM4E (0.95) | KDM4ENPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL4189211 | 0.88 | KDM4E (0.95) | KDM4ENPC1RAB9ASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9034873-B2 | Pyridazine and pyrrole compounds, processes for obtaining them and uses | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2015-05-19 | — | — | US | claimed |
| EP-2069345-A2 | PYRIDAZINE AND PYRROLE COMPOUNDS, PROCESSES FOR OBTAINING THEM AND USES | Centre National de la Recherche Scientifique (CNRS) (FR) | 2009-06-17 | — | — | EP | claimed |
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | claimed |
| WO-2008012440-A2 | PYRIDAZINE AND PYRROLE COMPOUNDS, PROCESSES FOR OBTAINING THEM AND USES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2008-01-31 | — | — | WO | claimed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | claimed |
| EP-1546150-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | Amura Therapeutics Limited (GB) | 2005-06-29 | — | — | EP | claimed |
| WO-2004007501-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | AMURA THERAPEUTICS LIMITED (GB) | 2004-01-22 | — | — | WO | claimed |
| US-9034873-B2 | Pyridazine and pyrrole compounds, processes for obtaining them and uses | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2015-05-19 | — | — | US | disclosed |
| US-9034873-B2 | Pyridazine and pyrrole compounds, processes for obtaining them and uses | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2015-05-19 | — | — | US | disclosed |
| US-9034873-B2 | Pyridazine and pyrrole compounds, processes for obtaining them and uses | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2015-05-19 | — | — | US | disclosed |
| US-20100298562-A1 | Pyridazine and Pyrrole Compounds, Processes For Obtaining Them and Uses | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2010-11-25 | — | — | US | disclosed |
| US-20100298562-A1 | Pyridazine and Pyrrole Compounds, Processes For Obtaining Them and Uses | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2010-11-25 | — | — | US | disclosed |
| US-20100298562-A1 | Pyridazine and Pyrrole Compounds, Processes For Obtaining Them and Uses | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2010-11-25 | — | — | US | disclosed |
| WO-2008043456-A1 | BENZOYLPYRAZOLES, THEIR USE AS AS HERBICIDES, AND INTERMEDIATES | BAYER CROPSCIENCE AG (DE) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008012440-A2 | PYRIDAZINE AND PYRROLE COMPOUNDS, PROCESSES FOR OBTAINING THEM AND USES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2008-01-31 | — | — | WO | disclosed |
| WO-2008012440-A2 | PYRIDAZINE AND PYRROLE COMPOUNDS, PROCESSES FOR OBTAINING THEM AND USES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2008-01-31 | — | — | WO | disclosed |
| WO-2007006714-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2007-01-18 | — | — | WO | disclosed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | disclosed |
| EP-1546150-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | Amura Therapeutics Limited (GB) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004007501-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | AMURA THERAPEUTICS LIMITED (GB) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298562-A1 | Pyridazine and Pyrrole Compounds, Processes For Obtaining Them and Uses | PPOX, PNPO, PLPBP | KDM4E 2333/4885NPC1 4663/4885RAB9A 4745/4885 |
| US-20060100431-A1 | Biologically active compounds | SOST, CTSK, CTSS | KDM4E 3911/4885NPC1 787/4885RAB9A 858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.